Marker Therapeutics (Marker Therapeutics) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 17, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Marker Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Marker Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Marker Therapeutics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Marker Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.

Marker Therapeutics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (Marker Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (NAS:MRKR) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

GX1:Germany

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Executives

Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Frederick Gerald Wasserman	director	4 NOBADEER DRIVE, PENNINGTON NJ 08534
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Peter L. Hoang	director, officer: CEO and President	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Norman David Eansor	director	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Juan Vera	director	2925 RICHMOND AVENUE, SUITE 1274, HOUSTON TX 77098